Metrics to compare | 6838 | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship Relationship6838PeersSector | |
|---|---|---|---|---|
P/E Ratio | −18.0x | 37.4x | −0.3x | |
PEG Ratio | 0.09 | 0.05 | 0.00 | |
Price/Book | 2.5x | 3.9x | 2.6x | |
Price / LTM Sales | 64.9x | 5.4x | 3.1x | |
Upside (Analyst Target) | - | 1.0% | 49.0% | |
Fair Value Upside | Unlock | −6.6% | 6.3% | Unlock |
Formosa Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, engages in developing drug candidates for ophthalmology, oncology, and anti-infectives in Taiwan. It is involved in developing TSY-110, an antibody-drug conjugate; and TSY-0210, an antibiotic for drug resistant infections. The company also develops APP13002 to treat infectious eye diseases, such as conjunctivitis, keratitis, blepharitis, and meibomian gland dysfunction; and MPT0E028, a novel pan- histone deacetylase inhibitor for solid tumors, such as hepatomas and colorectal cancer. It has a strategic partnership with Eyenovia, Inc. for the development of novel ophthalmic therapeutic; and Singapore Eye Research Institute to develop ophthalmic formulations for corneal diseases. Formosa Pharmaceuticals, Inc. was founded in 2010 and is headquartered in Taipei City, Taiwan.